"COPD Drugs Market in China 2016-2020" Published

Fast Market Research announces the availability of the new TechNavio report, "COPD Drugs Market in China 2016-2020", on their comprehensive research portal

Logo

Boston, MA -- (SBWire) -- 07/08/2016 --Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Get More Details on this Report and a Full Table of Contents at COPD Drugs Market in China 2016-2020

Technavio's analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class:

-Bronchodilators
-Phosphodiesterase-4 (PDE-4) inhibitors
-Steroids
-Combination therapies

Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-AstraZeneca
-Boehringer Ingelheim
-GSK
-Merck
-Novartis

Other prominent vendors

-Ache Laboratorios Farmaceuticos
-Almirall
-Aquinox Pharmaceuticals
-Ario Pharma
-BioMarck Pharmaceuticals
-Gilead Sciences
-Mereo BioPharma Group
-Mylan
-Orion
-Pearl Therapeutics
-Prosonix
-Teva Pharmaceutical Industry
-Theravance Biopharma
-Theron Pharmaceuticals
-Verona Pharma
-Xention
-ZAI Lab

Market driver

-Increase in environmental pollution
-For a full, detailed list, view our report

Market challenge

-Low diagnosis rate
-For a full, detailed list, view our report

Market trend

-Increased focus on combination therapies
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2020 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

Media Relations Contact

Bill Thompson
Director of Marketing
Fast Market Research, Inc.
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/703787